United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan 6 mg in 1 ml - busulfex is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. busulfex is contraindicated in patients with a history of hypersensitivity to any of its components. risk summary busulfex can cause fetal harm when administered to a pregnant woman based on animal data. busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. the solvent, dma, may also cause fetal harm when administered to a pregnant woman. in rats, dma doses of approximately 40% of the daily dose of dma in the busulfex dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see data ). there are no available human data informing the drug-associated risk. advise pregnant women of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - busulfan - oral suspension - 400microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - busulfan - oral solution - 400microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - busulfan - capsule - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution - busulfan - tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - busulfan - tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - busulfan - solution for infusion - 6mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - busulfan - solution for infusion - 6mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - neomycin sulfate -

United States - English - NLM (National Library of Medicine)

esp pharma, inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - injection - 60 mg in 10 ml - busulfex® (busulfan) injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. busulfex is contraindicated in patients with a history of hypersensitivity to any of its components.